Trial 5GYN-12-3

A Randomized, Open-Label, Phase II Study of the IDO Inhibitor INCB024360 versus Tamoxifen for Subjects with Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission with First-Line Chemotherapy.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Immunomodulator
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Agustin Garcia, M.D.
Other Trial Staff: Kristy Watkins, R.N., Grace Facio, R.N., Yvonne Flores, D.M., Yanli Wang, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.